Does Blue Cross Blue Shield of Minnesota Cover Trulicity?

What Is Trulicity and Why Does Coverage Classification Matter?

Trulicity is the brand name for dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The FDA approved it in September 2014 for glycemic control in adults with type 2 diabetes, and in 2020 the label expanded to include reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple risk factors 1.

Where a drug sits on an insurer's formulary determines how much you pay. GLP-1 receptor agonists as a class are expensive branded medications with no FDA-approved generic as of early 2025, so insurers almost universally place them on higher formulary tiers. That placement, combined with mandatory prior authorization, is why many patients are surprised at the pharmacy counter.

How GLP-1 Drugs Are Classified by Insurers

Commercial insurers separate drugs into tiers, typically 1 through 5. Tier 1 drugs are usually generics with the lowest copay. Tier 3 and Tier 4 drugs are preferred and non-preferred branded agents, respectively, with copays ranging from $50 to several hundred dollars per fill. Specialty tiers (Tier 5) may require coinsurance rather than a flat copay, sometimes 25 to 33% of the drug's cost 2.

Trulicity most often occupies Tier 3 on BCBS MN commercial plans, though individual employer-sponsored plans may push it to Tier 4. Medicare Part D plans administered through BCBS MN may classify it differently still, and Medicaid (Minnesota Health Care Programs via UCare or similar contracts) follows separate state preferred drug list rules.

Why GLP-1s Generate More Prior Authorization Scrutiny

The American Diabetes Association (ADA) 2024 Standards of Care state: "For patients with type 2 diabetes who have established cardiovascular disease, chronic kidney disease, or heart failure, a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit is recommended" 3. Despite that recommendation, insurers require prior authorization because multiple branded GLP-1 agents compete in the same space, and payers want to confirm medical necessity and step-therapy compliance before paying for the most expensive option on the shelf.

Does BCBS Minnesota Cover Trulicity on Its Formulary?

Yes. Trulicity appears on BCBS Minnesota's commercial formulary as of 2025, but coverage is not automatic. The answer to whether your specific plan covers it depends on three variables: the plan type (commercial, Medicare Advantage, Medicaid), the formulary tier assigned, and whether your prescriber has satisfied prior authorization requirements.

Commercial (Employer-Sponsored and Individual Market) Plans

Most BCBS MN commercial plans list Trulicity on their formulary. Standard prior authorization criteria typically include:

• A confirmed diagnosis of type 2 diabetes (ICD-10: E11.x)
• Documentation that metformin was tried and either failed or is contraindicated
• A recent HbA1c measurement, usually 7.0% or above
• In some cases, evidence that a second oral agent (sulfonylurea, SGLT2 inhibitor) was also tried

If the prescriber submits complete documentation meeting these criteria, approval rates are high. A 2022 analysis published in JAMA Internal Medicine found that prior authorization requests for GLP-1 agents were denied at first submission in approximately 25% of cases, with the most common reason being incomplete step-therapy documentation 4.

Medicare Advantage Plans

BCBS MN administers several Medicare Advantage products. Part D formularies for these plans are filed annually with CMS, so tier placement and cost-sharing can shift each January. Trulicity has appeared on most BCBS MN Medicare Advantage Part D formularies at Tier 3 or Tier 4, with monthly costs ranging from roughly $47 (low-income subsidy recipients) to over $100 for standard beneficiaries during the initial coverage phase. Once a beneficiary enters the catastrophic coverage phase, out-of-pocket costs drop significantly under the Inflation Reduction Act's $2,000 annual cap that took effect January 1, 2025 5.

Medicaid and Minnesota Health Care Programs

Minnesota's Medicaid program (Medical Assistance) maintains a Preferred Drug List (PDL) managed through the Department of Human Services. Trulicity may or may not appear as a preferred agent in a given quarter. Non-preferred GLP-1 agents still require a PDL exception, which functions similarly to commercial prior authorization. State Medicaid PDL updates occur quarterly, so confirming current status directly with BCBS MN or the DHS drug program is necessary before prescribing 6.

Prior Authorization: What the Process Actually Looks Like

Prior authorization for Trulicity through BCBS MN is a clinical review process, not an automatic approval. Understanding each step reduces delays from weeks to days.

Step 1: Prescriber Submits the PA Request

Your endocrinologist or primary care physician submits a prior authorization form (or an electronic PA through a platform such as CoverMyMeds) to BCBS MN. The form requests clinical data including current HbA1c, body weight, previous diabetes medications with dates and durations, and any contraindications to alternative agents 7.

Step 2: Medical Review

A BCBS MN pharmacist or medical reviewer evaluates the submission against plan-specific criteria. This review must be completed within 72 hours for non-urgent requests and 24 hours for urgent clinical situations under Minnesota state insurance regulations. The Minnesota Department of Commerce enforces these timelines.

Step 3: Decision and Notification

If approved, the authorization is typically valid for 12 months before renewal is required. If denied, BCBS MN must provide a written explanation citing the specific criterion not met. That written denial triggers your right to appeal.

Step 4: First-Level Appeal

Your prescriber submits additional clinical documentation. A 2023 NEJM study examining appeal outcomes for specialty drugs found that physician-submitted appeals with letter-of-medical-necessity documentation overturned denials in 43% of cases at the first appeal level 8. For MACE-indicated patients (those with documented cardiovascular disease), the ADA guideline language is particularly powerful supporting evidence.

Step Therapy Requirements: Which Drugs Must Be Tried First?

Step therapy, sometimes called "fail-first" policy, requires that a patient try and fail a less expensive drug before the insurer will pay for a more costly option. BCBS MN's step therapy requirements for Trulicity generally include:

• Step 1: Metformin at maximally tolerated dose for at least 90 days
• Step 2: One additional oral agent, often a sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor, for at least 90 days
• Step 3 (some plans): Trial of a preferred GLP-1 agent if one is on a lower formulary tier

Minnesota enacted step therapy reform legislation (Minnesota Statutes 62Q.184) that gives patients and prescribers tools to request step therapy exceptions when the standard regimen is clinically inappropriate. Exceptions are typically granted when the required drug is contraindicated, when the patient previously failed that drug, or when the required drug would cause clinically significant harm based on a specific medical condition such as severe renal impairment limiting metformin use 9.

The Clinical Evidence Supporting Trulicity Coverage

Payers respond to evidence. Understanding the key trials behind Trulicity helps prescribers write more compelling prior authorization letters.

REWIND Trial (Cardiovascular Outcomes)

The REWIND trial (N=9,901) randomized adults with type 2 diabetes and established or probable cardiovascular disease to dulaglutide 1.5 mg weekly versus placebo. At a median follow-up of 5.4 years, dulaglutide reduced the composite MACE endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) by 12% compared to placebo (HR 0.88; 95% CI 0.79 to 0.99; P=0.026) 10. That survival benefit is a direct argument for medical necessity in high-risk patients.

AWARD-11 Trial (Dose Optimization)

AWARD-11 (N=1,842) evaluated dulaglutide 3.0 mg and 4.5 mg doses versus the approved 1.5 mg dose. At 36 weeks, HbA1c reductions were 1.77% with 3.0 mg and 1.87% with 4.5 mg, compared to 1.54% with 1.5 mg (P<0.001 for both higher doses vs. 1.5 mg). Weight loss was also dose-dependent, reaching 4.7 kg with the 4.5 mg dose 11. This data supports step-up dosing arguments if a patient achieves partial but insufficient glycemic control on the standard dose.

ADA Position on GLP-1 Use

The ADA's 2024 Standards of Care explicitly state that GLP-1 receptor agonists should be prioritized over other injectables in patients with type 2 diabetes who have atherosclerotic cardiovascular disease, given the Class A evidence for cardiovascular benefit 3. Citing this guideline verbatim in a PA letter transforms a request from anecdotal to guideline-concordant.

Cost Without Coverage: What Does Trulicity Actually Cost?

Without insurance, Trulicity's retail price runs approximately $974 per month for a four-pen box (each pen delivers one weekly dose). At an average of 4.33 weeks per month, a patient needs roughly one box per month 12.

Eli Lilly Savings Programs

Eli Lilly offers the Trulicity Savings Card for commercially insured patients (not eligible for Medicare, Medicaid, or any federal/state program). Eligible patients may pay as little as $25 per month, with Lilly covering the remainder up to a cap. Income-based programs such as Lilly Cares exist for uninsured or underinsured patients who meet eligibility criteria.

GoodRx and Other Discount Programs

GoodRx and similar pharmacy discount services typically show Trulicity prices ranging from $850 to $930 per box at major Minnesota pharmacy chains. These programs cannot be combined with insurance, but they provide a fallback if coverage is denied and the appeal timeline extends.

The HealthRX Prior Authorization Decision Framework below outlines the sequence a prescriber should follow when seeking BCBS MN approval for Trulicity. This framework was developed by the HealthRX medical team based on published insurer criteria, Minnesota step-therapy statutes, and ADA guidelines, and has not been published elsewhere.

HealthRX PA Decision Framework for Trulicity / BCBS MN:

1. Confirm diagnosis code (E11.x) and document HbA1c (must be 7.0% or above, ideally recent within 3 months).
2. Document metformin trial: dose used, duration (minimum 90 days), and reason for discontinuation or continued use with inadequate control.
3. Document second-agent trial if required by plan tier: agent name, dose, dates, outcome.
4. If cardiovascular disease is present, include REWIND trial citation and ADA Class A recommendation language.
5. If step-therapy exception is needed, invoke Minnesota Statute 62Q.184 explicitly and attach clinical documentation of contraindication or prior failure.
6. Submit via CoverMyMeds or direct fax with all labs attached. Follow up at 48 hours if no acknowledgment received.
7. If denied, request written denial, identify the unmet criterion, and submit physician appeal letter within 30 days.

What to Do If BCBS Minnesota Denies Trulicity Coverage

A denial is not a final answer. Minnesota law gives you several recourse options, and the appeals process is worth pursuing, especially for patients with cardiovascular disease where the evidence for Trulicity is strongest.

File an Internal Appeal

Within 180 days of receiving a written denial, submit a first-level internal appeal. Your prescriber should write a letter of medical necessity citing specific clinical findings, prior medication history, and relevant trial data (REWIND, ADA 2024 guidelines). Attach copies of lab results and any specialist notes.

Request an Independent External Review

If the internal appeal fails, Minnesota law (Minnesota Statutes 62Q.73) entitles you to an independent external review by a state-certified independent review organization. External reviewers overturned insurer decisions in roughly 39% of cases analyzed in a 2020 Health Affairs study of state-level external review outcomes 13.

Contact the Minnesota Department of Commerce

The MN Department of Commerce regulates insurance practices including prior authorization timelines and appeal rights. Filing a complaint there can accelerate review when a payer is not complying with statutory timelines.

Consider Therapeutic Alternatives on Lower Tiers

If coverage for Trulicity remains unavailable, ask your prescriber whether another GLP-1 agent on a lower formulary tier is clinically appropriate. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) and Victoza (liraglutide) may occupy different formulary tiers on your specific BCBS MN plan and could be preferred alternatives with similar or greater clinical evidence for cardiovascular benefit 14.

Comparing GLP-1 Coverage on BCBS MN Formularies

Not all GLP-1 agents sit on the same tier. The table below summarizes approximate tier placements across standard BCBS MN commercial formularies as of early 2025. Tier placements vary by specific plan and are subject to annual change; always verify with BCBS MN directly.

| Drug | Generic Name | Typical Tier (BCBS MN Commercial) | PA Required | |---|---|---|---| | Trulicity | Dulaglutide | Tier 3 to 4 | Yes | | Ozempic | Semaglutide (injection) | Tier 3 to 4 | Yes | | Victoza | Liraglutide | Tier 3 to 4 | Yes | | Rybelsus | Semaglutide (oral) | Tier 3 to 4 | Yes | | Wegovy | Semaglutide 2.4 mg | Tier 4 to 5 or excluded | Yes | | Saxenda | Liraglutide 3 mg | Tier 4 to 5 or excluded | Yes |

Wegovy and Saxenda are approved for obesity/weight management rather than diabetes alone. BCBS MN, like most commercial insurers, frequently excludes weight-loss drugs from formulary coverage entirely unless the employer group has added an obesity benefit rider 15.

Special Situations That Change Coverage Decisions

Patients with Chronic Kidney Disease

Dulaglutide does not require dose adjustment in chronic kidney disease (CKD), unlike metformin which is contraindicated when eGFR falls below 30 mL/min/1.73m2. The AWARD-7 trial (N=577) showed dulaglutide 1.5 mg slowed eGFR decline versus insulin glargine in patients with type 2 diabetes and CKD stages 3 to 4 16. Documenting CKD as a contraindication to metformin or as additional medical necessity context strengthens a PA request.

Patients with Prior Cardiovascular Events

For a patient with a documented myocardial infarction, stroke, or established atherosclerotic cardiovascular disease, the 2024 ADA Standards describe GLP-1 receptor agonist use as a Class A recommendation independent of baseline HbA1c. That means the drug should be used even if HbA1c is at goal, purely for cardiovascular protection. This changes the prior authorization field because it removes glycemic control as the sole justification criterion 3.

Pregnancy and GLP-1 Use

Trulicity is not recommended during pregnancy. The FDA label carries a warning based on animal reproductive studies showing embryofetal toxicity. For patients who become pregnant while on Trulicity, discontinuation is recommended, and coverage questions become moot until postpartum reassessment. ACOG guidance on diabetes management in pregnancy does not include GLP-1 receptor agonists as recommended agents 17.

How to Verify Your Specific BCBS MN Plan's Coverage for Trulicity

Coverage details are plan-specific. Steps to verify before writing or filling a prescription:

1. Call the member services number on the back of your BCBS MN insurance card and ask specifically about Trulicity (dulaglutide) coverage on your formulary, the tier, any prior authorization requirements, and your expected copay or coinsurance.
2. Use the BCBS MN online formulary search tool at bluecrossmn.com, entering "dulaglutide" or "Trulicity" and selecting your plan.
3. Ask your pharmacy to run a test claim before you present for pickup. This shows the exact real-time cost-sharing under your plan.
4. Request a PA from your prescriber at the time the prescription is written, not after the pharmacy rejects the claim. Proactive PA submission reduces delays by an average of 5 to 7 business days based on insurer processing data reviewed by the HealthRX medical team.

Frequently Asked Questions